News | April 30, 2026
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
New medical and wellness centre combines on-site care with telehealth to support industrial workforce and surrounding communities
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Subscribe To Our Newsletter & Stay Updated
